Recent advances in the molecular pathogenesis of lymphomas

Current Opinion in Oncology

Volumn 11, Issue 5, 1999, Pages 351-363

  Sarris, Andreas ^a   Ford, Richard ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME INHIBITOR; PHOSPHOLIPASE C; PHOSPHOTRANSFERASE; PROTEIN BCL 2; PROTEINASE;

ANAPLASTIC CARCINOMA; APOPTOSIS; CANCER INVASION; CANCER SURVIVAL; CARCINOGENESIS; CHROMOSOME ABERRATION; CHROMOSOME INVERSION; DIFFERENTIAL DIAGNOSIS; ENZYME INHIBITION; GENOTYPE; HUMAN; IMMUNOPHENOTYPING; LYMPHOMA; MALIGNANT TRANSFORMATION; MOLECULAR GENETICS; MOLECULAR MODEL; MYELOMA; ONCOGENE; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

HUMANS; LYMPHOMA; PROTEIN KINASES; PROTO-ONCOGENES;

EID: 0032864389     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-199909000-00006     Document Type: Review

References (136)

1. Devesa SS, Fears T: Non-Hodgkin's lymphoma time trends: United States and international data. Cancer Research 1992, 52(suppl):5432-5440.
2. Holford TR, Zheng T, Mayne ST, McKay LA: Time trends of non-Hodgkin's lymphoma: are they real? What do they mean? Cancer Research 1992, 52(suppl):5443-5446.
3. Pearce N, Bethwaite P: Increasing incidence of non-Hodgkin's lymphoma: occupational and environmental factors. Cancer Research 1992, 52(suppl):5496-5500.
4. Greiner TC: Epidemiology of non-Hodgkin's lymphoma: a review. Diagn Oncol 1994, 95:26-32.
5. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. The non-Hodgkin's lymphoma pathologic classification project. Cancer 1982, 49:2112-2135.
6. Simon R, Durrleman S, Hoppe RT, Bonadonna G, Bloomfield CD, Rudders RA, et al.: The non-Hodgkin lymphoma pathologic classification project. Long-term follow-up of 1153 patients with non-Hodgkin lymphomas. Ann Intern Med 1988, 109:939-945.
7. Stansfeld AG, Diebold J, Noel H, Kapanci Y, Rilke F, Kelenyi G, et al.: Updated Kiel classification for lymphomas. Lancet 1988, 1:292-293.
8. Lennert K, Feller AC: Histopathology of non-Hodgkin's lymphomas (Based on the Updated Kiel Classification), Berlin, Germany: Springer-Verlag, 1992.
9. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, et al.: A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994, 84:1361-1392.
10. Pittaluga S, Bijnens L, Teodorovic I, Hagenbeek A, Meerwaldt JH, Somers R, et al.: Clinical analysis of 670 cases in two trials of the European Organization for the Research and Treatment of Cancer Lymphoma Cooperative Group subtyped according to the Revised European-American Classification of Lymphoid Neoplasms: a comparison with the working formulation. Blood 1996, 87:4358-4367.
11. Melnyk A, Rodriguez A, Pugh WC, Cabannillas F: Evaluation of the revised European-American lymphoma classification confirms the clinical relevance of immunophenotype in 560 cases of aggressive non-Hodgkin's lymphoma. Blood 1997, 89:4514-4520.
12. Armitage JO, Weisenburger DD: New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's lymphoma classification project. J Clin Oncol 1998, 16:2780-2795.
13. Lopez TM, Hagemeister FB, McLaughlin P, Velasquez WS, Swan F, Redman JR, et al.: Small noncleaved cell lymphoma in adults: superior results for stages I-III disease. J Clin Oncol 1990, 8:615-622.
14. Straus DJ, Wong GY, Liu J, Oppenberg J, Filippa DA, Gold JW, et al.: Small non-cleaved-cell lymphoma (undifferentiated lymphoma, Burkitt's type) in American adults: results with treatment designed for acute lymphoblastic leukemia. Am J Med 1991, 90:328-337.
15. Longo DL, Duffey PL, Jaffe ES, Raffeld M, Hubbard SM, Fisher RI, et al.: Diffuse small noncleaved-cell, non-Burkitt's lymphoma in adults: a highgrade lymphoma responsive to ProMACE-based combination chemotherapy. J Clin Oncol 1994, 12:2153-2159.
16. Magrath I, Adde M, Shad A, Venzon D, Seibel N, Gootenberg J, et al.: Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol 1996, 14:925-934.
17. Horning SJ: Low-grade lymphoma 1993: state of the art. Ann Oncol 1994, 5:23-27.
18. Romaguera JE, McLaughlin P, North L, Dixon D, Silvermintz KB, Garnsey LA, et al.: Multivariate analysis of prognostic factors in stage IV follicular low-grade lymphoma: a risk model. J Clin Oncol 1991, 9:762-769.
19. Tang SC, Visser L, Hepperle B, Hanson J, Poppema S: Clinical significance of bcl-2-MBR gene rearrangement and protein expression in diffuse large-cell non-Hodgkin's lymphoma: an analysis of 83 cases. J Clin Oncol 1994, 12:149-154.
20. Hermine O, Haioun C, Lepage E, d'Agay MF, Briere J, Lavignac C, et al.: Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood 1996, 87:265-272.
21. Gascoyne RD, Adomat SA, Krajewski S, Krajewska M, Horsman DE, Tolcher AW, et al.: Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. Blood 1997, 90:244-251.
22. Sanchez E, Chacon I, Plaza MM, Munoz E, Cruz MA, Martinez B, et al.: Clinical outcome in diffuse large B-cell lymphoma is dependent on the relationship between different cell-cycle regulator proteins. J Clin Oncol 1998, 16:1931-1939. Demonstrates the adverse effect of bcl-2 expression on outcomes of a clearly defined patient population with diffuse large cell lymphoma treated with doxorubicin-based therapy. The detection of t(14;18) does not affect outcome and is less frequent than bcl-2 expression. This suggests that bcl-2 is upregulated in many patients by mechanisms other than the t(14;18).
23. Kramer MH, Hermans J, Wijburg E, Philippo K, Geelen E, van Krieken JH, et al.: Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma. Blood 1998, 92:3152-3162. Confirms the association of bcl-2 expression with inferior outcome in aggressive lymphomas. References 22 (Sanchez et al: J Clin Oncol 1998, 16:1931-1939.) and 23, coupled with in vitro work (Sundaresan et al.: Cell Growth Differ 1997, 8:1071-1082) suggest that pharmacologic down regulation of bcl-2 levels by retinoids may be therapeutically useful.
24. Sarris AH, Medeiros LM, Khorana S, Herling M, Viviani S, Bonfante V, et al.: Bcl-2 is frequently expressed in Hodgkin-Reed-Sternberg cells and is associated with inferior failure-free survival in Hodgkin's disease treated with ABVD [abstract]. Ann Oncol 1999, 10(suppl3):72.
25. Stein H, Mason DY, Gerdes J, O'Connor N, Wainscoat J, Pallesen G, et al.: The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood 1985, 66:848-858.
26. Foss HD, Anagnostopoulos I, Araujo I, Assaf C, Demel G, Kummer JA, et al.: Anaplastic large-cell lymphomas of T-cell and null-cell phenotype express cytotoxic molecules. Blood 1996, 88:4005-4011.
27. Chan JK, Ng CS, Hui PK, Leung TW, Lo ES, Lau WH, McGuire LJ: Anaplastic large cell Ki-1 lymphoma. Delineation of two morphological types, Histopathology 1989, 15:11-34.
28. Pileri S, Falini B, Delsol G, Stein H, Baglioni P, Poggi S, et al.: Lymphohistiocytic T-cell lymphoma (anaplastic large cell lymphoma CD30+/Ki-1 + with a high content of reactive histiocytes). Histopathology 1990, 16:383-391.
29. Kinney MC, Collins RD, Greer JP, Whitlock JA, Sioutos N, Kadin ME: A small-cell-predominant variant of primary Ki-1 (CD30)+ T-cell lymphoma. Am J Surg Pathol 1993, 17:859-868.
30. Kinney MC, Glick AD, Stein H, Collins RD: Comparison of anaplastic large cell Ki-1 lymphomas and microvillous lymphomas in their immunologic and ultrastructural features. Am J Surg Pathol 1990, 14:1047-1060.
31. Chan JK, Buchanan R, Fletcher CD: Sarcomatoid variant of anaplastic large-cell Ki-1 lymphoma. Am J Surg Pathol 1990, 14:983-988.
32. Pileri SA, Piccaługa A, Poggi S, Sabatini E, Piccalugga PP, De Vivo A, et al.: Anaplastic large cell lymphoma: update of findings. Leuk Lymphoma 1995, 18:17-25.
33. Morris SW, Kirstein MN, Valentine MB, Dittmer KG, Shapiro DN, Saltman DL, Look AT: Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 1994, 263:1281-1284.
34. Morris SW, Naeve C, Mathew P, James PL, Kirstein MN, Cui X, Witte DP: ALK, the chromosome 2 gene locus altered by the t(2; 5) in non-Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK). Oncogene 1997, 14:2175-2188.
35. Shiota M, Fujimoto J, Semba T, Satoh H, Yamamoto T, Mori S: Hyperphosphorylation of a novel 80 kDa protein-tyrosine kinase similar to Ltk in a human Ki-1 lymphoma cell line, AMS3. Oncogene 1994, 9:1567-1574.
36. Fujimoto J, Shiota M, Iwahara T, Seki N, Satoh H, Mori S, Yamamoto T: Characterization of the transforming activity of p80, a hyperphosphorylated protein in a Ki-1 lymphoma cell line with chromosomal translocation t(2; 5). Proc Natl Acad Sci USA 1996, 93:4181-4186.
37. Bischof D, Pulford K, Mason DY, Morris SW: Role of the nucleophosmin (NPM) portion of the non-Hodgkin's lymphoma-associated NPM-anaplastic lymphoma kinase fusion protein in oncogenesis. Mol Cell Biol 1997, 17:2312-2325.
38. Bai RY, Dieter P, Peschel C, Morris SW, Duyster J: Nucleophosminanaplastic lymphoma kinase of large-cell anaplastic lymphoma is a constitutively active tyrosine kinase that utilizes phospholipase C-gamma to mediate its mitogenicity. Mol Cell Biol 1998, 18:6951-6961. Molecular characterization of the targets phosphorylated by the constitutively active NPM-ALK fusion protein.
39. Kuefer MU, Look AT, Pulford K, Behm FG, Pattengale PK, Mason DY, Morris SW: Retrovirus-mediated gene transfer of NPM-ALK causes lymphoid malignancy in mice. Blood 1997, 90:2901-2910.
40. Morris SW, Shurtleff SA, Head D, Behm FG, Raimondi SC, Weisenburger DD, et al.: Molecular detection of the t(2;5) of non-Hodgkin's lymphoma (NHL) by reverse transcriptase-polymerase chain reaction. Blood 1994, 84(suppl 1):37a.
41. Waggott W, Lo YM, Bastard C, Gatter KC, Leroux D, Mason DY, et al.: Detection of NPM-ALK DNA rearrangement in CD30 positive anaplastic large cell lymphoma. Br J Haematol 1995, 89:905-907.
42. Sarris AH, Luthra R, Papadimitracopoulou V, Waadsorp M, Dimopoulos MA, McBride JA, et al.: Amplification of genomic DNA demonstrates the presence of the t(2;5)(p23;q35) in anaplastic large cell lymphoma, but not on other non-Hodgkin's lymphomas, Hodgkin's disease, or lymphomatoid papulosis. Blood 1996, 88:1771-1779.
43. Sarris AH, Luthra R, Padimitracopoulou V, Waasporp M, Dimopoupos MA, McBride JA, et al.: Rapid amplification of genomic DNA detects the t(2;5)(p23;q35) in anaplastic large-cell lymphoma, but not in other non-Hodgkin's lymphomas, Hodgkin's disease, or lymphomatoid papulosis. Ann Oncol 1997, 8(suppl 2):59-63.
44. Shiota M, Nakamura S, Ichinohasama R, Abe M, Akagi T, Takeshita M, et al.: Anaplastic large cell lymphomas expressing the novel chimeric protein p80NPM/ALK: a distinct clinicopathologic entity. Blood 1995, 86:1954-1960.
45. Pittaluga S, Wiodarska I, Pulford K, Campo E, Morris SW, Van den Berghe H, De Wolf-Peeters C: The monoclonal antibody ALK1 identifies a distinct morphological subtype of anaplastic large cell lymphoma associated with 2p23/ALK rearrangements. Am J Pathol 1997, 151:343-351.
46. Pulford K, Lamant L, Morris SW, Butler LH, Wood KM, Stroud D, et al.: Detection of anaplastic lymphoma kinase (ALK) and nucleolar protein nucleophosmin (NPM) ALK proteins in normal and neoplastic cells with the monoclonal antibody ALK1. Blood 1997, 89:1394-1404.
47. Delsol G, Lamant L, Mariame B, Pulford K, Dastugue N, Brousset P, et al.: A new subtype of large B-cell lymphoma expressing the ALK kinase and lacking the 2;5 translocation. Blood 1997, 89:1483-1490.
48. Sarris AH, Luthra R, Cabanillas F, Morris SW, Pugh WC: Genomic DNA amplification and the detection of t(2;5)(p23;q35) in lymphoid neoplasms. Leuk Lymphoma 1998, 29:507-514.
49. Sarris AH, Jhanwar SC, Cabanillas F: Cytogenetics of Hodgkin's disease. In Hodgkin's disease. Edited by Mauch PM, Armitage JO, Diehl V, Hoppe RT, Weiss LM. New York: Lippincott-Raven, 1999.
50. Luthra R, Pugh WC, Waasdorp M, Morris W, Cabanillas F, Chan PK, Sarris AH: Mapping of genomic t(2;5)(p23;q35) break points in patients with anaplastic large cell lymphoma by sequencing long-range PCR products. Hematopathol Mol Hematol 1998, 11:173-183. Confirms the presence of unique breakpoints for each patient, which may be used for patient-specific disease monitoring.
51. Wlodarska I. De Wolf-Peeters C. Falini B, Verhoef G, Morris SW, Hagemeijer A, Van den Berghe H: The cryptic inv(2)(p23q35) defines a new molecular genetic subtype of ALK-positive anaplastic large-cell lymphoma. Blood 1998, 92:2688-2695. Activation of ALK by a chromosomal inversion without t(238)(p32;q35).
52. Benharroch D, Meguerian-Bedoyan Z, Lamant L, Amin C, Brugieres L, Terrier-Lacombe MJ, et al.: ALK-positive lymphoma: a single disease with abroad spectrum of morphology. Blood 1998, 91:2076-2084. Defines the ALCL as a distinct clinicopathologic entity on the basis of expression of the ALK-fusion protein.
53. Falini B, Bigerna B, Fizzotti M, Pulford K, Pileri SA, Delsol G, et al.: ALK expression defines a distinct group of T/null lymphomas ("ALK lymphomas") with a wide morphological spectrum. Am J Pathol 1998, 153:875-886. Defines the ALCL as a distinct clinicopathologic entity on the basis of expression of the ALK-fusion protein.
54. Falini B, Pileri S, Zinzani L, Carbone A, Zagonei V, Wolf-Peeters C, et al.: ALK + lymphoma: clinico-pathological findings and outcome. Blood 1999, 93:2697-2706. Defines the ALCL as a distinct clinicopathologic entity on the basis of enpression of the ALK-fusion protein.
55. Mason DY, Pulford KA, Bischof D, Kuefer MU, Butler LH, Lamant L, et al.: Nucleolar localization of the nucleophosmin-anaplastic lymphoma kinase is not required for malignant transformation. Cancer Res 1998, 58:1057-1062. Transformation by the constitutively active ALK-fusion protein does not require nuclear localization. Since the fusion protein is a constitutively active kinase, it suggests that its targets are dispersed throughout the cell.
56. ten Berge RL, Dukers DF, Oudejans JJ, Pulford K, Ossenkoppele GJ, de Jong D, et al.: Adverse effects of activated cytotoxic T lymphocyte on the clinical outcome of nodal anaplastic large cell lymphoma. Blood 1999, 93:2688-2696.
57. Greer JP. Flexner JM, Kallianpur AR, Goodman SA, Stein RS, Whitlock JM, et al.: Ki-1 + anaplastic large cell lymphoma (ALCL): correlation of clinical features with p80NPM/ALK expression and histology. Blood 1996, 88(suppl 1):224a.
58. Herling M, Pugh W, Romaguera J, Morris SW, Falini B, Cabanillas F, Sarris AH: The t(2;5) and failure-free survival (FFS) of adults with anaplastic large cell lymphoma (ALCL). Blood 1999, 92(suppl 1):224b.
59. Zucca E, Bertoni F, Roggero E, Bosshard G, Cazzaniga G, Pedrinis E, et al.: Molecular analysis of the progression from Helicobacter pylori-associated chronic gastritis to mucosa-associated lymphoid-tissue lymphoma of the stomach. N Engl J Med 1998, 338:804-810. Elegant description of molecular changes during the emergence of gastric MALT lymphomas.
60. Roggero E, Zucca E, Pinotti G, Pascarella A, Capelta C, Savio A, et al.: Eradication of Helicobacter pylori infection in primary low-grade gastric lymphoma of mucosa-associated lymphoid tissue. Ann Intern Med 1995, 122:767-769.
61. Zucca E, Roggero E, Pileri S: B-cell lymphoma of MALT type: a review with special emphasis on diagnostic and management problems of low-grade gastric tumours. Br J Haematol 1998, 100:3-14.
62. Thiede C, Alpen B, Morgner A, Schmidt M, Ritter M, Ehninger G, et al.: Ongoing somatic mutations and clonal expansions after cure of Helicobacter pylori infection in gastric mucosa-associated lymphoid tissue B-cell lymphoma. J Clin Oncol 1998, 16:3822-3831.
63. Zucca E, Bertoni F, Roggero E, Cazzaniga G, Bosshard G, Biondi A, Cavalli F: Autorcactive B cell clones in marginal-zone B cell lymphoma (MALT lymphoma) of the stomach [letter]. Leukemia 1998, 12:247-249.
64. Du M, Peng H, Singh N, Isaacson PG, Pan L: The accumulation of p53 abnormalities is associated with progression of mucosa-associated lymphoid tissue lymphoma. Blood 1995, 86:4587-4593.
65. Auer IA, Gascoyne RD, Connors JM, Cotter FE, Greiner TC, Sanger WG, Horsman DE: t(11;18)(q21;q21) is the most common translocation in MALT lymphomas. Ann Oncol 1997, 8:979-985.
66. Ott G, Katzenberger T, Greiner A, Kalla J, Rosenwald A, Heinrich U, et al.: The t(11;18)(q21;q21) chromosome translocation is a frequent and specific aberration in low-grade but not high-grade malignant non-Hodgkin's lymphomas of the mucosa-associated lymphoid tissue (MALT-) type. Cancer Res 1997, 57:3944-3948.
67. Willis TG, Jadayel DM, Du MK, Plug H, Perry AR, Abdul-Rauf M, et al.: Bcl-10 is involved in t(1:14)(p22:q32) of MALT B cell lymphoma and mutated in multiple tumor types. Cell 1999, 96:35-45. Cloning of bcl-10 and descriptions of mutations involving this novel locus in various lymphomas. It precise role in the pathogenesis of NHL is still unclear.
68. Zhang Q, Siebert R, Yan M, Hinzmann B, Cui X, Xue L, et al.: Inactivating mutations and overexpression of BCL10, a caspase recruitment domain (CARD)-containing gene, in MALT lymphoma with t(1;14)(p22;q32). Nature Genetics 1999, 22:63-68. Cloning of bcl-10 and descriptions of mutations involving this novel locus in various lymphomas. Its precise role in the pathogenesis of NHL is still unclear.
69. Barberis A. Widenhorn K, Vitelli L, Busslinger M: A novel B cell lineage-specific transcription factor present at early but not late stages of differentiation. Genes Dev 1990, 4:849-859.
70. Adams B, Dorfler P, Aguzzi A, Kozmik Z, Urbanek P, Maurer-Fogy I, Busslinger M: Pax-5 encodes the transcription factor BSAP and is expressed in B lymphocytes, the developing CNS, and adult testis. Genes Dev 1992, 6:1589-1607.
71. Ohno H, Furukawa T, Fukuhara S, Zong SQ, Kamesaki H, Shows TB, et al.: Molecular analysis of a chromosomal translocation, t(9;14)(p13;q32), in a diffuse large-cell lymphoma cell line expressing the Ki-1 antigen. Proc Natl Acad Sci U S A 1990, 87:628-632.
72. Urbanek P, Wang ZQ, Fetka I, Wagner EF, Busslinger M: Complete block of early B cell differentiation and altered patterning of the posterior midbrain in mice lacking Pax5/BSAP. Cell 1994, 79:901-912.
73. Nutt SL, Urbanek P, Rolink A, Busslinger M: Essential functions of Pax5 (BSAP) in pro-B cell development: difference between fetal and adult B lymphopoiesis and reduced V-to-DJ recombination at the IgH locus. Genes Dev 1997, 11:476-491.
74. Morrison AM, Nutt SL, Thevenin C, Rolink A, Busslinger M: Loss- and gain- of-function mutations reveal an important role of BSAP (Pax-5) at the start and end of B cell differentiation. Semin Immunol 1998, 10:133-142.
75. Iida S, Rao PH, Nallasivam P, Hibshoosh H, Butler M, Louie DC, et al.: The t(9;14)(p13;q32) chromosomal translocation associated with lymphoplasmacytoid lymphoma involves the PAX 5 gene. Blood 1996, 88:4110-4117. Alteration of PAX-5 in a case of marginal zone lymphoma. The role of this locus in small lymphocytic lymphomas should be further defined.
76. Bergsagel PL, Chesi M, Nardini E, Brents LA, Kirby SL, Kuehl WM: Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma. Proc Natl Acad Sci USA 1996, 93:13931-13936.
77. Chesi M, Bergsagel PL, Shonukan OO, Martelli ML, Brents LA, Chen T, et al.: Frequent dysregulation of the c-maf proto-oncogene at 16q23 by translocation to an lg locus in multiple myeloma. Blood 1998, 91:4457-4463. Alterations of c-maf may offer clues into the pathogenesis of multiple myeloma.
78. Chesi M, Nardini E, Brents LA, Schrock E, Ried T, Kuehl WM, Bergsagel PL: Frequent translocation t(4;14)(p16,3:q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nature Genetics 1997, 16:260-264.
79. Chesi M, Nardini E, Lim RS, Smith KD, Kuehl WM, Bergsagel PL: The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts. Blood 1998, 92:3025-3034. Rearrangements of BFGFR3 and of MMSET are a possible cause of multiple myeloma. The precise molecular mechanisms should be investigated further.
80. Cattoretti G, Chang CC, Cechova K, Zhang J, Ye BH, Falini B, et al.: BCL-6 protein is expressed in germinal-center B cells. Blood 1995, 86:45-53.
81. Falini B, Fizzotti M, Pileri S, Liso A, Pasqualucci L, Flenghi L: Bcl-6 protein expression in normal and neoplastic lymphoid tissues. Ann Oncol 1997, 8:101-104.
82. Lo Coco F, Ye BH, Lista F, Corradini P, Offit K, Knowles DM, et al.: Rearrangements of the BCL6 gene in diffuse large cell non-Hodgkin's lymphoma. Blood 1994, 83:1757-1759.
83. Carbone A, Gloghini A, Gaidano G, Dalla-Favera R, Falini B: BCL-6 protein expression in human peripheral T-cell neoplasms is restricted to CD30+ anaplastic large-cell lymphomas. Blood 1997, 90:2445-2450.
84. Offit K, Lo Coco F, Louie DC, Parsa NZ, Leung D, Portlock C. et al.: Rearrangement of the bcl-6 gene as a prognostic marker in diffuse large-cell lymphoma. N Engl J Med 1994, 331:74-80.
85. Bastard C, Deweindt C, Kerckaert JP, Lenormand B, Rossi A, Pezzella F, et al.: LAZ3 rearrangements in non-Hodgkin's lymphoma: correlation with histology, immunophenotype, karyotype, and clinical outcome in 217 patients. Blood 1994, 83:2423-2427.
86. Vitolo U, Gaidano G, Botto B, Volpe G, Audisio E, Bertini M, et al.: Rearrangements of bcl-6, bcl-2, c-myc and 6q deletion in B-diffuse large-cell lymphoma: clinical relevance in 71 patients. Ann Oncol 1998, 9:55-61. Rearrangement of bcl-6 does not significantly affect prognosis in diffuse large B-cell NHL. This contradicts previously published data.
87. Liang R, Chan WP, Kwong YL, Chan AC, Xu WS, Srivastava G: Mutation of the 5' noncoding region of the BCL-6 gene in low-grade gastric lymphoma of the mucosa-associated lymphoid tissue. Cancer Genet Cytogenet 1998, 102:110-113.
88. Carbone A, Gloghini A, Gaidano G, Franceschi S, Capello D, Drexler HG, et al.: Expression status of BCL-6 and syndecan-1 identifies distinct histogenetic subtypes of Hodgkin's disease. Blood 1998, 92:2220-2228.
89. Flenghi L, Bigerna B, Fizzotti M, Venturi S, Pasqualucci L, Pileri S, et al.: Monoclonal antibodies PG-B6a and PG-B6p recognize, respectively, a highly conserved and a formol-resistant epitope on the human BCL-6 protein amino-terminal region. Am J Pathol 1996, 148:1543-1555.
90. Dyomin VG, Rao PH, Dalla-Favera R, Chaganti RSK: BCL8, a novel gene involved in translocations affecting band 15q11-13 in diffuse large-cell lymphoma. Proc Natl Acad Sci U S A 1997, 94:5728-5732.
91. Miyashita T, Reed JC: Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood 1993, 81:151-157.
92. Yunis JJ, Oken MM, Kaplan ME, Ensrud KM, Howe RR, Theologides A: Distinctive chromosomal abnormalities in histologic subtypes of non-Hodgkin's lymphoma. N Engl J Med 1982, 307:1231 -1236.
93. Tsujimoto Y, Gorham J, Cossman J, Jaffe E, Croce CM: The t(14; 18) chromosome translocations involved in B-cell neoplasms result from mistakes in VDJ joining. Science 1985, 229:1390-1393.
94. Cleary ML, Sklar J: Nucleotide sequence of a t(14; 18) chromosomal breakpoint in follicular lymphoma and demonstration of a breakpoint-cluster region near a transcriptionally active locus on chromosome 18. Proc Natl Acad Sci U S A 1985, 82:7439-7443.
95. Cleary ML, Galili N, Sklar J: Detection of a second t(14; 18) breakpoint cluster region in human follicular lymphomas. J Exp Med 1986, 164:315-320.
96. Graninger WB, Seto M, Boutain B, Goldman P, Korsmeyer SJ: Expression of Bcl-2 and Bcl-2-lg fusion transcripts in normal and neoplastic cells. J Clin Invest 1987, 80:1512-1515.
97. Lee MS, Chang KS, Cabanillas F, Freireich EJ, Trujillo JM, Stass SA: Detection of minimal residual cells carrying the t(14; 18) by DNA sequence amplification. Science 1987, 237:175-178.
98. Gribben JG, Freedman A, Woo SD, Blake K, Shu RS, Freeman G, et al.: All advanced stage non-Hodgkin's lymphomas with a polymerase chain reaction amplifiable breakpoint of bcl-2 have residual cells containing the bcl-2 rearrangement at evaluation and after treatment. Blood 1991, 78:3275-3280.
99. Zelenetz AD, Chu G, Galili N, Bangs CD, Horning SJ, Donlon TA, et al.: Enhanced detection of the t(14; 18) translocation in malignant lymphoma using pulsed-field gel electrophoresis. Blood 1991, 78:1552-1560.
100. Wang YL, Addya K, Edwards RH, Rennert H, Dodson L, Leonard DG, Wilson RB: Novel bcl-2 breakpoints in patients with follicular lymphoma. Diagn Mol Pathol 1998, 7:85-89.
101. Lopez-Guillermo A, Cabanillas F, McLaughlin P, Smith T, Hagemeister F, Rodriguez MA, et al.: The clinical significance of molecular response in indolent follicular lymphomas. Blood 1998, 91:2955-2960. Achievement of a molecular response is a treatment-related variable associated with prolonged disease-free survival. If confirmed, this surrogate endpoint may significantly shorten the duration of clinical trials in follicular lymphomas.
102. Limpens J, de Jong D, van Krieken JH, Price CG, Young BD, van Ommen GJ, Kluin PM: Bcl-2/JH rearrangements in benign lymphoid tissues with follicular hyperplasia. Oncogene 1991, 6:2271-2276.
103. Aster JC, Kobayashi Y, Shiota M, Mori S, Sklar J: Detection of the t(14; 18) at similar frequencies in hyperplastic lymphoid tissues from American and Japanese patients. Am J Pathol 1992, 141:291-299.
104. Liu Y, Hernandez AM, Shibata D, Cortopassi GA: Bcl-2 translocation frequency rises with age in humans. Proc Natl Acad Sci U S A 1994. 91:8910-8914.
105. Limpens J, Stad R, Vos C, da Vlaam C, de Jong D, van Ommen GJB, et al.: Lymphoma-associated translocation t(14;18) in blood B cells of normal individuals. Blood 1995, 85:2528-2536.
106. Dolken G, Illerhaus G, Hirt C, Mertelsmann R: BCL-2/JH rearrangements in circulating B cells of healthy blood donors and patients with nonmalignant diseases. J Clin Oncol 1996, 14:1333-1344.
107. Nomdedeu JF, Baiget M, Gaidano G, Estivill C, Lasa A, Rubiol E, et al.: p53 mutation in a case of blastic transformation of follicular lymphoma with double bcl-2 rearrangement (MBR and VCR). Leuk Lymphoma 1998, 29:595-605.
108. Elenitoba-Johnson KS, Gascoyne RD, Lim MS, Chhanabai M, Jaffe ES, Raffeld M: Homozygous deletions at chromosome 9p21 involving p16 and p15 are associated with histologic progression in follicle center lymphoma. Blood 1998, 91:4677-4685.
109. Sundaresan A, Claypool K, Mehta K, Lopez-Berestein G, Cabanillas F, Ford RJ Jr: Retinoid-mediated inhibition of cell growth with stimulation of apoptosis in aggressive B-cell lymphomas. Cell Growth Differ 1997, 8:1071-1082. Possible therapeutic way to reduce bcl-2 levels.
110. Voorzanger N, Touitou R, Garcia E, Delecluse HJ, Rousset F, Joab I, et al.: Interleukin (IL)-10 and IL-6 are produced in vivo by non-Hodgkin's lymphoma cells and act as cooperative growth factors. Cancer Res 1996, 56:5499-5505.
111. Taga K, Cherney B, Tosato G: IL-10 inhibits apoptotic cell death in human T cells starved of IL-2. Int Immunol 1993, 5:1599-1608.
112. Taga K, Chretien J, Cherney B, Diaz L, Brown M, Tosato G: Interleukin-10 inhibits apoptotic cell death in infectious mononucleosis T cells. J Clin Invest 1994, 94:251-260.
113. Brunetti M, Martelli N, Colasante A, Piantelli M, Musiani P, Aiello FB: Spontaneous and glucocorticoid induced apoptosis in human mature T lymphocytes. Blood 1995, 86:4199.
114. Weber-Nordt RM, Henschler R, Schott E, Wehinger J, Behringer D, Mertelsmann R, Finke J: Interleukin-10 increases Bcl-2 expression and survival in primary human CD34+ hematopietic progenitor cells. Blood 1996, 88:2549-2558.
115. Voorzanger-Rousselot N, Favrot M-C, Blay JY: Resistance to cytotoxic chemotherapy induced by CD40 ligand in lymphoma cells. Blood 1998, 92:3381-3387.
116. Blay JY, Burdin N, Rousset F, Lenoir G, Biron P, Philip I, et al.: Serum interleukin-10 in non-Hodgkin's lymphoma: a prognostic factor. Blood 1993, 82:2169-2174.
117. Stasi R, Zinzani L, Galieni P, Lauta VM, Damasio E, Dispensa E, et al.: Detection of soluble interleukin-2 receptor and interleukin-10 in the serum of patients with aggressive non-Hodgkin's lymphoma. Identification of a subset at high risk of treatment failure. Cancer 1994, 74:1792-1800.
118. Stasi R, Zinzani PL, Galieni P, Lauta VM. Damasio E, Dispensa E, et al.: Prognostic value of serum IL-10 and soluble IL-2 receptor levels in aggressive non-Hodgkin's lymphoma. Br J Haematol 1994, 88:770-777.
119. Sarris AH, Viviani S, Bonfante V, Kliche KO, Notti P, Peethambaram P, et al.: A prognostic model of Hodgkin's disease (HD) based on IL-10. Blood 1998, 92(suppl 1):991a.
120. Sarris AH, Kliche KO, Pethambaram P, Preti A, Tucker S, Jackow C, Messina O, et al.: Interleukin-10 levels are often elevated In serum of adults with Hodgkin's disease and are associated with inferior failure-free survival. Ann Oncol 1999, 10:1-8.
121. Sarris AH, Viviani S, Bonfante V, Kliche KO, Notti P, Pethambaram P, et al.: Serum IL-10 elevation and failure-free survival of Hodgkin's disease treated with radiotherapy. Br J Heamatol 1999, Haematologica 1999, 84:116. Elevation of serum IL-10 is associated with inferior failure-free survival in Hodgkin's disease. Similar results have been reported for non-Hodgkin's lymphomas. Elucidation of the involved mechanisms may provide targets for therapeutic intervention. These may include monoclonal antibodies against IL-10 or its receptor, IL-10 receptor-binding antagonists, or pharmacologic down-regulation of bcl-2 levels.
122. Küpers R, Hansmann ML, Rajewsky K: Clonality and germinal centre B-cell derivation of Hodgkin? Reed-Sternberg cells in Hodgkin's disease. Ann Oncol 1998, 9(suppl 5):S17-320.
123. Kuppers R, Rajewsky K: The origin of Hodgkin and Reed/Sternberg cells in Hodgkin's disease. Ann Rev Immunol 1998, 16:471-493.
124. Marafioti T, Hummel M, Anagnostopoulos I, Foss HD, Falini B, Delsol G, et al.: Origin of nodular lymphocyte-predominant Hodgkin's disease from a clonal expansion of highly mutated germinal-center B cells. N Engl J Med 1997, 337:453-458.
125. Sarris AH, Medeiros LJ, Herling M, Khorana S, Kliche KO, Mesina O, et al.: The expression of the EBV-coded latent membrane protein-1 (LMP-1) in Reed-Sternberg cells of Hodgkin's disease (HD) is associated with higher serum IL-10 levels and inferior failure-free survival (FFS). Blood 1998, 92(suppl 1):353a.
126. Kenney JL, Guinness ME, Curiel T, Lacy J: Antisense to the epstein-barr virus (EBV)-encoded latent membrane protein 1 (LMP-1) suppresses LMP-1 and bcl-2 expression and promotes apoptosis in EBV-immortalized B cells. Blood 1998, 92:1721-1727.
127. Santon A, Manzanal A, Campo A, Bellas C: Deletions in the Epstein-Barr virus latent membrane protein-1 oncogene in Hodgkin's disease. J Clin Pathol Mol Pathol 1995, 48:M184-M187.
128. Dolcetti R, Quaia M, Gloghini A, De Re V, Zancai P, Cariati R, et al.: Biologically relevant phenotypic changes and enhanced growth properties induced in B lymphocytes by an EBV strain derived from a histologically aggressive Hodgkin's disease. Intl J Cancer 1999, 80:240-249.
129. Knecht H, Raphael M, McQuain C, Rothenberger S, Pihan G, Camilleri-Broet S, et al.: Deletion variants within the NF-kappa B activation domain of the LMP1 oncogene prevail in acquired immunodeficiency syndrome-related large cell lymphomas and human immunodeficiency virus-negative atypical lymphoproliferations. Blood 1996, 87:876-881.
130. Knecht H, Brousset P, Bachmann E, Sandvej K, Odermatt BF: Latent membrane protein 1 : a key oncogene in EBV-related carcinogenesis? Acta Haematologica 1993, 90:167-171.
131. Barth S, Klimka A, Matthey B, Haier B, Kube D, Tesch H, et al.: Cytokine fusion toxins show specific potency against Hodgkin lymphoma cells in vitro. Leuk Lymphoma 1998, 29(suppl 1):107.
132. Nadali G, Tavecchia L, Zanolin E, Bonnfante V, Viviani S, Camerini E, et al.: Serum level of the soluble form of CD30 molecule identifies patients with Hodgkin's disease at high risk of unfavorable outcome. Blood 1998, 91:3011-3016. Soluble CD30 may be useful both as a prognostic feature and as a tumor marker in Hodgkin's disease. It has already been shown to be a tumor marker and prognostic in patients with ALCL. Investigation of possible mechanisms underlying its association with inferior outcomes may offer clues for new therapy.
133. Dürkop H, Foss H-D, Demel G, Klotzbach H, Hahn C, Stein H: Tumor necrosis factor receptor-associated factor 1 is overexpressed in Reed-sternberg cells of Hodgkin's disease and Epstein-Barr virus-transformed lymphoid cells. Blood 1999, 93:617-623.
134. Bargou RC, Emmerich F, Krappmann D, Bommert K, Mapara MY, Arnold W, et al.: Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. J Clin Invest 1997, 100:2961-2969.
135. Gravel S, Delsol G, AI Saati T: Single-cell analysis of the t(14;18)(q32;q21) chromosomal translocation in Hodgkin's disease demonstrates the absence of this translocation in neoplastic Hodgkin and Reed-Sternberg cells. Blood 1998, 91:2866-2874.
136. Willis TG, Zalcberg IR, Coignet LJ, Wlodarska I, Stul M, Jadayel DM, et al.: Molecular cloning of translocation t(1;14)(q21;q32) defines a novel gene (BCL9) at chromosome 1q21. Blood 1998, 91:1873-1881. Cloning of bcl-9. It's role in lymphomagenesis is still undefined.